The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

Introduction: Opicapone (OPC) was efficacious in reducing OFF-time in two pivotal trials in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (BIPARK-I and -II). Post-hoc analyses of these trials evaluated the efficacy of OPC following pre-defined segmentation of the wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha, José-Francisco, Ebersbach, Georg, Lees, Andrew, Tolosa, Eduardo, Ferreira, Joaquim J., Poewe, Werner, Rascol, Olivier, Stocchi, Fabrizio, Antonini, Angelo, Magalhães, Diogo, Gama, Helena, Soares-da-Silva, Patrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603564/
https://www.ncbi.nlm.nih.gov/pubmed/34803891
http://dx.doi.org/10.3389/fneur.2021.754016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603564/
https://www.ncbi.nlm.nih.gov/pubmed/34803891
http://dx.doi.org/10.3389/fneur.2021.754016

Ejemplares similares